Table 1.
Drug | Authors | Animal/cell | Disease model | Administration | Effects | Signaling pathways |
---|---|---|---|---|---|---|
HRW | Iketani et. al 20176 |
C57BL/6 mice | Septic liver injury (LPS) | HRW po. × 3d | 4-HNE↓, 8-OHdG ↓ | HO-1 ↑ |
2% H2 | Qiu et. al 201113 |
C57BL/6 mice | Septic lung injury (LPS) | 2% H2 inhalation× 2h | MDA ↓, SOD ↑ | Nitro tyrosine (NT) ↓ |
HRW | Muramatsu et. al 201616 |
Sprague-Dawley rats, A549 | Bronchopulmonary Dysplasia (LPS) | HRW po. × 10d | 8-OHdG ↓, ROS ↓ | HO-1 ↑ |
HRS | Dong et. al 201720 |
ICR mice | Pulmonary Fibrosis (LPS) | HRS 2.5, 5 or 10 ml/kg/d× 8d i.p. | MDA ↓, T-AOC ↑, SOD ↑, CAT ↑ | N/A |
HRS | Xu et. al 201322 |
Sprague-Dawley rats | Septic liver injury (LPS) | HRS 8 ml/kg/h i.v.× 6h | MDA ↓, MPO ↓ | NF-κB ↓, Smac ↓, MAPK(JNK/P38) ↓ |
HRS | Li et. al 201323 |
Sprague-Dawley rats | Sepsis (CLP) | HRS 5 ml/kg/h i.p. (0, 6, 18h after CLP) |
MDA ↓, SOD ↑ | N/A |
2% H2 | Xie et. al 201024 |
C57BL/6 mice | Sepsis (CLP) | 2% H2 inhalation (4L/min) | SOD ↑, CAT↑ | N/A |
2% H2 | Liu et. al 201425 |
Wistar rats | Septic shock (LPS) |
2% H2 inhalation× 4h | MDA ↓, MPO ↓, SOD ↑ | N/A |
HRW | Zhang et. al 201427 |
Sprague-Dawley rats | Septic peritonitis injury (LPS/CLP) | HRW 6 ml/kg/d po. × 10d | MDA ↓, MPO ↓ | NF-κB ↓ |
HRS/W/M: hydrogen rich saline/water/media, LPS: Lipopolysaccharide, CLP: cecal ligation and puncture, MDA: malondialdehyde, SOD: superoxide dismutase, MPO: myeloperoxidase, CAT: catalase, 4-NHE: 4-hydroxy-2-nonenal, 8-OHdG: 8-hydroxy-2'-deoxyguanosine, ROS: reactive oxygen species, i.p.: Intraperitoneal injection, i.v.: Intravenous injection, po.: oral administration.